CL2020000070A1 - Agentes, usos y métodos para el tratamiento. - Google Patents

Agentes, usos y métodos para el tratamiento.

Info

Publication number
CL2020000070A1
CL2020000070A1 CL2020000070A CL2020000070A CL2020000070A1 CL 2020000070 A1 CL2020000070 A1 CL 2020000070A1 CL 2020000070 A CL2020000070 A CL 2020000070A CL 2020000070 A CL2020000070 A CL 2020000070A CL 2020000070 A1 CL2020000070 A1 CL 2020000070A1
Authority
CL
Chile
Prior art keywords
treatment
agents
methods
antibodies
sortiline
Prior art date
Application number
CL2020000070A
Other languages
English (en)
Inventor
Ibrahim John Malik
Jan Egebjerg
Arnout Gerritsen
Paul Parren
Rønn Lars Christian Billmann
Soren Christensen
Tina Stummann
De Brink Edward Van
Esben Trabjerg
Kasper Dyrberg Rand
Jeffrey B Stavenhagen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2020000070A1 publication Critical patent/CL2020000070A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS MONOCLONALES ANTI-SORTILINA QUE SE HA ENCONTRADO QUE SON ÚTILES EN LA CORRECCIÓN DE UN NIVEL DEFICIENTE DE PROGRANULINA (PGRN). EN PARTICULAR, ESTOS ANTICUERPOS PUEDEN USARSE EN EL TRATAMIENTO DE LA DEMENCIA FRONTOTEMPORAL (DFT) Y LA ESCLEROSIS LATERAL AMIOTRÓFICA (ELA) Y OTROS TRASTORNOS NEURODEGENERATIVOS, TALES COMO LA ENFERMEDAD DE ALZHEIMER (EA).
CL2020000070A 2017-07-20 2020-01-09 Agentes, usos y métodos para el tratamiento. CL2020000070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201700419 2017-07-20

Publications (1)

Publication Number Publication Date
CL2020000070A1 true CL2020000070A1 (es) 2020-06-12

Family

ID=63113476

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000070A CL2020000070A1 (es) 2017-07-20 2020-01-09 Agentes, usos y métodos para el tratamiento.

Country Status (25)

Country Link
US (2) US10894833B2 (es)
EP (1) EP3655438A2 (es)
JP (1) JP2020527152A (es)
KR (1) KR20200031610A (es)
CN (1) CN110945029A (es)
AR (1) AR112563A1 (es)
AU (1) AU2018303175A1 (es)
BR (1) BR112019005428A2 (es)
CA (1) CA3069391A1 (es)
CL (1) CL2020000070A1 (es)
CO (1) CO2019014090A2 (es)
CR (1) CR20200027A (es)
DO (1) DOP2020000006A (es)
EA (1) EA201992688A1 (es)
EC (1) ECSP20002935A (es)
IL (1) IL271728B2 (es)
JO (1) JOP20200007A1 (es)
MA (1) MA49633A (es)
NI (1) NI202000005A (es)
PE (1) PE20210467A1 (es)
PH (1) PH12019502869A1 (es)
RU (1) RU2019140933A (es)
SG (1) SG11201912228WA (es)
TW (1) TW201908342A (es)
WO (1) WO2019016247A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280441B1 (en) 2015-04-07 2021-09-29 Alector LLC Anti-sortilin antibodies and methods of use thereof
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
KR20230065382A (ko) 2018-07-13 2023-05-11 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법
KR20210134321A (ko) * 2019-02-01 2021-11-09 노바록 바이오테라퓨틱스 리미티드 항-클라우딘 18 항체 및 이의 이용 방법
WO2023247754A1 (en) 2022-06-23 2023-12-28 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0486622B1 (en) 1989-08-09 1998-11-04 Rhomed, Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5101990A (en) 1990-03-23 1992-04-07 Continental Pet Technologies, Inc. Stretch blow molded oblong or oval container
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
WO2001009187A2 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
HUE031611T2 (en) 2006-12-21 2017-07-28 H Lundbeck As Modulation of Pronurotrophin Activity
EP2185692A4 (en) 2007-08-10 2012-05-02 Medarex Inc HCO32 AND HCO27 AND RELATED EXAMPLES
CA2712276A1 (en) * 2008-01-16 2009-07-23 Neurodyn, Inc. Treating neurodegenerative diseases with progranulin (pgrn)
CN102131826B (zh) 2008-04-27 2014-07-02 H.隆德贝克有限公司 人类分拣蛋白的晶体结构及其用于鉴定分拣蛋白的配体的用途
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
US20120039865A1 (en) 2008-08-19 2012-02-16 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN105641694B (zh) 2008-12-19 2020-08-14 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
WO2014071131A1 (en) 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
US10149836B2 (en) * 2014-03-21 2018-12-11 The Board Of Regents Of The University Of Texas System Isoxazole treatments for frontotemporal dementia
IL295414A (en) * 2014-03-27 2022-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema as a result of diabetes
EP3280441B1 (en) * 2015-04-07 2021-09-29 Alector LLC Anti-sortilin antibodies and methods of use thereof
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
KR20220083863A (ko) * 2017-04-05 2022-06-20 심포젠 에이/에스 Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
KR20230065382A (ko) * 2018-07-13 2023-05-11 알렉터 엘엘씨 항-소틸린 항체 및 이들의 사용 방법
CN113151432A (zh) * 2020-04-14 2021-07-23 郁金泰 神经退行性疾病检测和治疗的新靶标

Also Published As

Publication number Publication date
IL271728B1 (en) 2024-01-01
EP3655438A2 (en) 2020-05-27
EA201992688A1 (ru) 2020-05-20
ECSP20002935A (es) 2020-02-28
WO2019016247A3 (en) 2019-06-20
US20210292414A1 (en) 2021-09-23
DOP2020000006A (es) 2020-07-15
CR20200027A (es) 2020-04-17
SG11201912228WA (en) 2020-01-30
CO2019014090A2 (es) 2020-01-17
TW201908342A (zh) 2019-03-01
AR112563A1 (es) 2019-11-13
JOP20200007A1 (ar) 2020-01-15
CN110945029A (zh) 2020-03-31
IL271728B2 (en) 2024-05-01
JP2020527152A (ja) 2020-09-03
PH12019502869A1 (en) 2020-09-28
RU2019140933A3 (es) 2021-10-28
WO2019016247A2 (en) 2019-01-24
PE20210467A1 (es) 2021-03-08
IL271728A (en) 2020-02-27
AU2018303175A1 (en) 2020-01-16
RU2019140933A (ru) 2021-08-20
MA49633A (fr) 2020-05-27
US20190023788A1 (en) 2019-01-24
KR20200031610A (ko) 2020-03-24
US10894833B2 (en) 2021-01-19
NI202000005A (es) 2020-05-20
BR112019005428A2 (pt) 2019-07-16
CA3069391A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
DOP2016000195A (es) Compuestos
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
MD3261720T2 (ro) Anticorpi anti-Tau și utilizările acestora
CO2017012988A2 (es) Agentes, usos y métodos para el tratamiento
CR20160394A (es) Heteroaril amidas como inhibidores de agregación de proteína
EA201990400A1 (ru) Соединения и композиции и их применение
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2019006495A (es) Tratamiento de enfermedades neurologicas.
EA202090414A1 (ru) Соединения и их применение
MX2017012397A (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2017006692A (es) Trastornos neurodegenerativos.
PH12021550213A1 (en) Methods for treating neurodegenerative disorders
MX2019001804A (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
EA201792076A1 (ru) Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний
MA40908B1 (fr) Anticorps anti-il-6 améliorés